diltiazem has been researched along with perhexiline in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 13 (65.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (25.00) | 29.6817 |
| 2010's | 2 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Martre, H; Singlas, E; Taburet, AM | 1 |
| Briscoe, MG; Smith, HJ | 1 |
| Lewis, JG | 1 |
| Donath, M; Ebner, F; Rämsch, KD | 1 |
| Deierkauf, M; Elferink, JG | 1 |
| Becker, HJ; Dowinsky, S; Hopf, R; Kaltenbach, M; Kober, G | 1 |
| Dipalma, JR | 1 |
| Antman, EM; Braunwald, E; Muller, JE; Stone, PH | 1 |
| Hayakawa, H; Kimura, E; Kishida, H; Kusama, Y; Otsu, F; Takayama, M | 1 |
| Kimura, M; Ono, H | 1 |
| Nayler, WG | 1 |
| Flaim, SF; Zelis, R | 1 |
| Aziza, JP; Blanchard, D; Guermonprez, JL; Lancelin, B; Maurice, P | 1 |
6 review(s) available for diltiazem and perhexiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Clinical pharmacology of calcium inhibitors].
Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers; Diltiazem; Dogs; Half-Life; Humans; Intestinal Absorption; Kidney Failure, Chronic; Kinetics; Liver Diseases; Metabolic Clearance Rate; Nifedipine; Perhexiline; Protein Binding; Pyrrolidines; Rats; Tissue Distribution; Verapamil | 1985 |
Adverse reactions to calcium antagonists.
Topics: Calcium Channel Blockers; Diltiazem; Drug Interactions; Humans; Kinetics; Lidoflazine; Nifedipine; Perhexiline; Prenylamine; Risk; Verapamil | 1983 |
Clinical differentiation of nifedipine and other calcium antagonists.
Topics: Biological Availability; Calcium Channel Blockers; Diltiazem; Drug Tolerance; Heart Diseases; Hemodynamics; Humans; Kinetics; Nifedipine; Perhexiline; Verapamil | 1984 |
[Treatment of angina pectoris with calcium antagonists].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Diltiazem; Drug Therapy, Combination; Exercise Test; Fendiline; Humans; Nicardipine; Nifedipine; Perhexiline; Prenylamine; Propafenone; Propiophenones; Verapamil | 1982 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Coronary Circulation; Diltiazem; Hemodynamics; Humans; Myocardial Contraction; Nifedipine; Nitrogen; Perhexiline; Piperidines; Pyridines; Regional Blood Flow; Vasodilation; Verapamil | 1980 |
14 other study(ies) available for diltiazem and perhexiline
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
The relative sensitization by acidosis of five calcium blockers in cat papillary muscles.
Topics: Acidosis; Animals; Calcium Channel Blockers; Cats; Diltiazem; In Vitro Techniques; Lidoflazine; Myocardial Contraction; Nifedipine; Papillary Muscles; Perhexiline; Verapamil | 1985 |
The effect of verapamil and other calcium antagonists on chemotaxis of polymorphonuclear leukocytes.
Topics: Animals; Calcium; Calcium Channel Blockers; Cell Survival; Chemotaxis, Leukocyte; Diltiazem; Gallopamil; Magnesium; Neutrophils; Perhexiline; Prenylamine; Rabbits; Verapamil | 1984 |
Calcium channel blockers.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem; Half-Life; Heart Diseases; Humans; Hypertension; Kinetics; Myocardial Infarction; Nifedipine; Perhexiline; Vasodilator Agents; Verapamil | 1983 |
Effects of calcium antagonists, especially nifedipine, on variant angina, resting angina, and unstable angina.
Topics: Aged; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Coronary Vasospasm; Diltiazem; Female; Humans; Male; Middle Aged; Nifedipine; Perhexiline; Prenylamine; Pyridines; Rest; Verapamil | 1982 |
Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
Topics: Adenosine Diphosphate; Adolescent; Adult; Calcium; Collagen; Diltiazem; Epinephrine; Humans; In Vitro Techniques; Male; Nifedipine; Perhexiline; Platelet Aggregation; Vasodilator Agents; Verapamil | 1981 |
Calcium antagonists.
Topics: Angina Pectoris; Calcium Channel Blockers; Cell Membrane; Diltiazem; Heart; Humans; Hypertension; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Myocardial Infarction; Myocardium; Nifedipine; Perhexiline; Verapamil | 1980 |
Clinical use of calcium entry blockers.
Topics: Angina Pectoris; Calcium Channel Blockers; Cinnarizine; Coronary Circulation; Coronary Vasospasm; Diltiazem; Flunarizine; Heart Rate; Humans; Lidoflazine; Nifedipine; Perhexiline; Verapamil | 1981 |
[Calcium inhibitors. Current indications in cardiology].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Diltiazem; Humans; Nifedipine; Perhexiline; Prenylamine; Verapamil | 1980 |